Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
Open Access
- 8 January 2025
- journal article
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 21, 100922
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 36 references indexed in Scilit:
- Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protectionAmerican Journal of Preventive Cardiology, 2023
- Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registryAmerican Heart Journal, 2023
- Comparative cardiovascular effects of GLP‐1 agonists using real‐world dataEndocrinology, Diabetes & Metabolism, 2023
- Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)Diabetes Therapy, 2021
- Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisThe Lancet, 2021
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United StatesEndocrinology, Diabetes & Metabolism, 2019
- Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RACurrent Diabetes Reports, 2018
- Diabetes Complications Severity Index (DCSI)—Update and ICD-10 translationJournal of Diabetes and its Complications, 2017
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysisClinical Therapeutics, 2015